Predicting risk of radiation-induced lung injury.
暂无分享,去创建一个
Hubert Thierens | Indira Madani | H. Thierens | W. De Neve | J. V. van Meerbeeck | K. De Ruyck | I. Madani | Jan Van Meerbeeck | Kim De Ruyck | Wilfried De Neve | Hannelore Goeminne | H. Goeminne
[1] Joos V Lebesque,et al. Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: re-evaluation of dose in normal lung tissue. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] D. Abraham,et al. Constitutive Connective Tissue Growth Factor Expression in Scleroderma Fibroblasts Is Dependent on Sp1* , 2003, Journal of Biological Chemistry.
[3] P. Hasleton,et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. , 1998, Transplantation.
[4] S. Lario,et al. Smoking increases serum levels of transforming growth factor-beta in diabetic patients. , 1999, Diabetes care.
[5] Barbara Vanderstraeten,et al. Accuracy of patient dose calculation for lung IMRT: A comparison of Monte Carlo, convolution/superposition, and pencil beam computations. , 2006, Medical physics.
[6] J. Overgaard,et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. , 1996, Journal of the National Cancer Institute.
[7] Ken-ichi Yoshida,et al. Evaluation of serum KL-6 as a predictive marker of radiation pneumonitis in patients with breast-conservation therapy , 2004, International Journal of Clinical Oncology.
[8] J. Itami,et al. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. , 2004, Chest.
[9] R. Clough,et al. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis , 1997 .
[10] B. Jeremic,et al. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. , 2003, Anticancer research.
[11] M T Munley,et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. , 1997, International journal of radiation oncology, biology, physics.
[12] D. Schultz,et al. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. , 1996, International journal of radiation oncology, biology, physics.
[13] P. Okunieff,et al. Circulating IL-6 as a predictor of radiation pneumonitis. , 2001, International journal of radiation oncology, biology, physics.
[14] LENT SOMA scales for all anatomic sites. , 1995, International journal of radiation oncology, biology, physics.
[15] G. Ceresoli,et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] R. Clough,et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[17] M. Anscher,et al. In regard to De Jaeger et al.: significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer (INT J RADIAT ONCOL BIOL PHYS 2004;58:1378-1387). , 2005, International journal of radiation oncology, biology, physics.
[18] A. Hajeer,et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients , 2003, International journal of radiation biology.
[19] L. Marks. Physiology-based studies of radiation-induced normal tissue injury. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] S. McDonald,et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. , 1995, International journal of radiation oncology, biology, physics.
[21] Michael Lock,et al. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[22] M. Washington,et al. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. , 1996, Lung cancer.
[23] C. Arteaga,et al. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. , 1998, Experimental cell research.
[24] Mann-Jy Chen,et al. Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor-α to Its Two Receptors (*) , 1995, The Journal of Biological Chemistry.
[25] J. Blay,et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R K Ten Haken,et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.
[27] R. Clough,et al. Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. , 2003, International journal of radiation oncology, biology, physics.
[28] R. Clough,et al. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.
[29] Y. Ishii,et al. Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. , 1999, The European respiratory journal.
[30] M. Southey,et al. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. , 2001, International journal of radiation oncology, biology, physics.
[31] H. Kampinga,et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.
[32] P Baas,et al. Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. , 2000, International journal of radiation oncology, biology, physics.
[33] M. Di Nisio,et al. Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. , 2002, American journal of hypertension.
[34] D. Gandara,et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] James B. Mitchell,et al. Amelioration of Radiation-induced Fibrosis , 2004, Journal of Biological Chemistry.
[36] M. Dewhirst,et al. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. , 2005, International journal of radiation oncology, biology, physics.
[37] M. Anscher,et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. , 1997, International journal of radiation oncology, biology, physics.
[38] R K Ten Haken,et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. , 1994, International journal of radiation oncology, biology, physics.
[39] S. Chanock,et al. SNPs in cancer research and treatment , 2004, British Journal of Cancer.
[40] S. Gordon. Alternative activation of macrophages , 2003, Nature Reviews Immunology.
[41] Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? , 2005, International journal of radiation oncology, biology, physics.
[42] M. Martin,et al. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? , 2000, International journal of radiation oncology, biology, physics.
[43] R. Henriksson,et al. Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[44] D. Venzon,et al. The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. , 2005, Chest.
[45] Kyriaki Theodorou,et al. Evaluation of dose–response models and parameters predicting radiation induced pneumonitis using clinical data from breast cancer radiotherapy , 2005, Physics in medicine and biology.
[46] B. Camoretti-Mercado,et al. Transforming growth factor-β1 and disorders of the lung , 2007, Cell Biochemistry and Biophysics.
[47] N. Saijo,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] P. Okunieff,et al. Radiation pneumonitis and early circulatory cytokine markers. , 2002, Seminars in radiation oncology.
[49] M. Anscher,et al. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. , 1998, Lung cancer.
[50] S. Kelly,et al. Radiation pneumonitis in patients treated for breast cancer. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[51] A. Rosenthal,et al. Clinical Investigation , 2003, Advances in Experimental Medicine and Biology.
[52] Matthias Wjst,et al. Target SNP selection in complex disease association studies , 2004, BMC Bioinformatics.
[53] K. Sugimura,et al. Clinical significance of serum pulmonary surfactant proteins a and d for the early detection of radiation pneumonitis. , 2001, International journal of radiation oncology, biology, physics.
[54] Masahiro Endo,et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. , 2003, International journal of radiation oncology, biology, physics.
[55] J A Purdy,et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.
[56] B. Jeremic,et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] A. Pfeiffer,et al. Elevated Plasma Levels of Transforming Growth Factor-β1 in NIDDM , 1996, Diabetes Care.
[58] J. Bradley. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. , 2005, Seminars in oncology.
[59] R. Stock,et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. , 2002, International journal of radiation oncology, biology, physics.
[60] K. Shin,et al. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol. , 1993, International journal of radiation oncology, biology, physics.
[61] Olivier De Wever,et al. Role of tissue stroma in cancer cell invasion , 2003, The Journal of pathology.
[62] Mary Helen Barcellos-Hoff,et al. Radiation and the microenvironment – tumorigenesis and therapy , 2005, Nature Reviews Cancer.
[63] S. Kudoh,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] S. Abe,et al. Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. , 2001, The European respiratory journal.
[65] N. Gross. Pulmonary effects of radiation therapy. , 1977, Annals of internal medicine.
[66] Lawrence B Marks,et al. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. , 2002, International journal of radiation oncology, biology, physics.
[67] C. Cheng,et al. TGF-beta3 regulates the blood-testis barrier dynamics via the p38 mitogen activated protein (MAP) kinase pathway: an in vivo study. , 2003, Endocrinology.
[68] M. V. van Herk,et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. , 2002, International journal of radiation oncology, biology, physics.
[69] RobertI Miller,et al. Lung V20 measurements: In regard to Seppenwoolde et al. (Int J Radiat Oncol Biol Phys 2003;55:724-735), and Tsujino et al. (Int J Radiat Oncol Biol Phys 2003;56:1208-1209). , 2004, International journal of radiation oncology, biology, physics.
[70] L. Boersma,et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] Andrew Jackson,et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. , 2004, International journal of radiation oncology, biology, physics.
[72] K Hirata,et al. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. , 1998, European journal of cancer.
[73] M. Yokota,et al. Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. , 2000, Circulation.
[74] Joos V Lebesque,et al. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.
[75] T. Dix,et al. Redox-mediated activation of latent transforming growth factor-beta 1. , 1996, Molecular endocrinology.
[76] P Schraube,et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. , 1995, International journal of radiation oncology, biology, physics.
[77] J. Bernier,et al. Quantitative clinical radiobiology of early and late lung reactions. , 2000, International journal of radiation biology.
[78] G. Rodrigues. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[79] T. Kodama,et al. Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy , 2006, Medical oncology.
[80] K. Flanders,et al. Smad3 as a mediator of the fibrotic response , 2004, International journal of experimental pathology.
[81] M. Anscher,et al. Radiation-induced lung injury. , 2003, Seminars in radiation oncology.
[82] Andrew Jackson,et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. , 2002, International journal of radiation oncology, biology, physics.
[83] S. Tucker,et al. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[84] Lawrence B Marks,et al. Dosimetric predictors of radiation-induced lung injury. , 2002, International journal of radiation oncology, biology, physics.
[85] P. Riley. Free radicals in biology: oxidative stress and the effects of ionizing radiation. , 1994, International journal of radiation biology.
[86] N. Kohno,et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. , 1988, Japanese journal of clinical oncology.
[87] N. Kohno,et al. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. , 1992, Chest.
[88] R. Leduc,et al. Processing of Transforming Growth Factor 1 Precursor by Human Furin Convertase (*) , 1995, The Journal of Biological Chemistry.
[89] Michael Baumann,et al. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. , 2005, International journal of radiation oncology, biology, physics.
[90] R. Komaki,et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. , 1998, International journal of radiation oncology, biology, physics.
[91] G J Kutcher,et al. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[92] C. Streffer,et al. Radiopathology of Organs and Tissues , 1991, Medical Radiology.
[93] Steve Webb,et al. Prediction of radiation-induced normal tissue complications in radiotherapy using functional image data , 2005, Physics in medicine and biology.
[94] N. Nissen,et al. Late effects on pulmonary function of mantle‐field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease , 1990, European journal of haematology.
[95] C. De Wagter,et al. Lethal pneumonitis in a phase I study of chemotherapy and IMRT for NSCLC: the need to investigate the accuracy of dose computation. , 2005, Radiotherapy and Oncology.
[96] R. Clough,et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. , 2001, International journal of radiation oncology, biology, physics.
[97] Stephanie Green,et al. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.
[98] Y. Maehara,et al. Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin , 1997, International journal of cancer.
[99] N. Willich,et al. The bronchiolar epithelium as a prominent source of pro-inflammatory cytokines after lung irradiation. , 2004, International journal of radiation oncology, biology, physics.
[100] J. Yarnold,et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[101] T. Spector,et al. Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.
[102] Riley Pa. Free Radicals in Biology: Oxidative Stress and the Effects of Ionizing Radiation , 1994 .
[103] F. Shepherd,et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. , 1999, International journal of radiation oncology, biology, physics.
[104] R. Jaszczak,et al. The time course of radiation therapy-induced reductions in regional perfusion: a prospective study with >5 years of follow-up. , 2002, International journal of radiation oncology, biology, physics.
[105] J. Chang-Claude,et al. A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer , 2003 .
[106] L. Marks,et al. Challenges in defining radiation pneumonitis in patients with lung cancer. , 2005, International journal of radiation oncology, biology, physics.
[107] Henrik Lindberg,et al. Transforming Growth Factor-β1 Specifically Induce Proteins Involved in the Myofibroblast Contractile Apparatus* , 2004, Molecular & Cellular Proteomics.
[108] M. Barcellos-Hoff,et al. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. , 1998, Radiation research.
[109] J. Overgaard,et al. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[110] D. Cox,et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. , 2003, Cancer research.
[111] M T Munley,et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. , 2001, International journal of radiation oncology, biology, physics.
[112] M Paesmans,et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients , 2004, British Journal of Cancer.
[113] N. Barthelemy-Brichant. Determination of TGF-beta1 plasma levels: In regard to Anscher et al. (Int J Radiat Oncol Biol Phys 2003;56: 988-995) and de Jaeger et al (Int J Radiat Oncol Biol Phys 2004;58: 1378-1387). , 2004, International journal of radiation oncology, biology, physics.
[114] H. Thierens,et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. , 2005, International journal of radiation oncology, biology, physics.
[115] M. Barcellos-Hoff,et al. Latent transforming growth factor β1 activation in situ: quantitative and functional evidence after low‐dose γ‐irradiation 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[116] D. Payne,et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] Junwei Yang,et al. Transforming Growth Factor-β1 Potentiates Renal Tubular Epithelial Cell Death by a Mechanism Independent of Smad Signaling* , 2003, The Journal of Biological Chemistry.
[118] Marks Lb. Physiology-based studies of radiation-induced normal tissue injury. , 1999 .
[119] A. Pfeiffer,et al. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. , 1996, Diabetes care.
[120] R. Jaszczak,et al. The effect of patient-specific factors on radiation-induced regional lung injury. , 1999, International journal of radiation oncology, biology, physics.
[121] MitsuhiroYokota,et al. Association of a T29→C Polymorphism of the Transforming Growth Factor-β1 Gene With Genetic Susceptibility to Myocardial Infarction in Japanese , 2000 .
[122] H. Thierens,et al. TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. , 2006, International journal of radiation oncology, biology, physics.
[123] A. Laggner,et al. Increased levels of transforming growth factor-beta1 in essential hypertension. , 2001, American journal of hypertension.
[124] P. Rubin,et al. Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. , 2005, International journal of radiation oncology, biology, physics.
[125] A. Kubo,et al. Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. , 2004, Respiratory medicine.
[126] P. Willcox,et al. The effect of irradiation on lung function and perfusion in patients with lung cancer. , 1995, International journal of radiation oncology, biology, physics.
[127] M. Frid,et al. Hypoxia, leukocytes, and the pulmonary circulation. , 2005, Journal of applied physiology.
[128] Joos V Lebesque,et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. , 2003, International journal of radiation oncology, biology, physics.
[129] H. Groen,et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[130] H. Ueoka,et al. Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer. , 1997, International journal of radiation oncology, biology, physics.
[131] J. Overgaard,et al. Time course of radiological lung density changes after postmastectomy radiotherapy. , 2000, Acta oncologica.
[132] J. Purdy,et al. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. , 1995, International journal of radiation oncology, biology, physics.
[133] B. Camoretti-Mercado,et al. Transforming growth factor-beta1 and disorders of the lung. , 2005, Cell biochemistry and biophysics.
[134] C. Arlett,et al. Four radiation hypersensitivity cases and their implications for clinical radiotherapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[135] J. Peacock,et al. Normal cellular radiosensitivity in an adult Fanconi anaemia patient with marked clinical radiosensitivity. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[136] Y. Nagasaka,et al. Assessment of serum CYFRA 21‐1 in lung cancer , 1996, Cancer.
[137] A. Albert,et al. Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms , 2002, European journal of clinical investigation.